Key Details
Price
$106.00Last Dividend
$0.52Annual ROE
87.29%Beta
0.80Events Calendar
Next earnings date:
Feb 05, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 02, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
Aug 16, 2024Next split:
N/ARecent split:
Sept 20, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's dominance in the weight-loss drug sector. Novo's $16.5 billion acquisition of Catalent aims to alleviate supply issues, with EU antitrust approval likely, enhancing Wegovy's production capacity.
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. Management expects CagriSema to generate 25% weight loss after 68 weeks of treatment. Based on the mechanism of action and phase 2 results in obese patients and type 2 diabetes patients, I agree and expect CagriSema to generate 24-27% weight loss.
Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source familiar with the matter has told Reuters.
In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis): Novo Nordisk NYSE:NVO (Wegovy) and Eli Lilly NYSE:LLY (Zepbound) Today I read this: WEIGHT-LOSS DRUG COVERAGE RISES AMONG LARGE US
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.
Bagsværd, Denmark, 13 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Bagsværd, Denmark, 12 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
When it comes to weight loss drugs, Ozempic has become a phenomenon.
FAQ
- What is the primary business of Novo Nordisk A/S?
- What is the ticker symbol for Novo Nordisk A/S?
- Does Novo Nordisk A/S pay dividends?
- What sector is Novo Nordisk A/S in?
- What industry is Novo Nordisk A/S in?
- What country is Novo Nordisk A/S based in?
- When did Novo Nordisk A/S go public?
- Is Novo Nordisk A/S in the S&P 500?
- Is Novo Nordisk A/S in the NASDAQ 100?
- Is Novo Nordisk A/S in the Dow Jones?
- When was Novo Nordisk A/S's last earnings report?
- When does Novo Nordisk A/S report earnings?